Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 4, 2025 • 10:00 AM ET

Date/Time Source News Release
12/31/2024 04:05 PM EST Business Wire CEL-SCI Announces Closing of $5 Million Offering
12/29/2024 08:41 PM EST Business Wire CEL-SCI Announces Pricing of $5 Million Public Offering
12/12/2024 09:15 AM EST Business Wire CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
11/07/2024 08:15 AM EST Business Wire U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
10/22/2024 09:15 AM EDT Business Wire FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
10/01/2024 06:00 AM EDT Business Wire CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
09/16/2024 07:30 AM EDT Business Wire CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
09/10/2024 09:32 AM EDT Business Wire CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
09/04/2024 09:00 AM EDT Business Wire The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
08/15/2024 08:00 AM EDT Business Wire CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
Page

Additional News

As of January 4, 2025 • 10:00 AM ET

Date/Time Source News Release
12/30/2024 01:06 AM EST SeekingAlpha CEL-SCI prices $5 million offering
12/27/2024 05:12 PM EST SeekingAlpha CEL-SCI announces proposed public offering of common stock
12/19/2024 12:59 PM EST Baystreet From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector
11/08/2024 08:00 AM EST SeekingAlpha Stock Picks From Seeking Alpha's October 2024 New Analysts
11/07/2024 11:31 AM EST SeekingAlpha CEL-SCI, FDA agree on Phase 3 trial design for cancer drug
10/25/2024 05:25 PM EDT SeekingAlpha CEL-SCI files to sell 1M shares of common stock for holders
08/15/2024 08:24 AM EDT SeekingAlpha Cel-Sci GAAP EPS of -$0.42 misses by $0.31
08/02/2024 08:30 AM EDT InvestorBrandNetwork InvestorNewsBreaks - CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering
07/26/2024 10:24 AM EDT SeekingAlpha CEL-SCI stock rallies 40% on Multikine study analysis results
07/26/2024 10:00 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Fri, Jul 26, 2024 as of 10.00 am ET
Page